Axelopran/oxycodone

Drug Profile

Axelopran/oxycodone

Alternative Names: Oxycodone/alexopran; Oxycodone/TD-1211; TD-1211/oxycodone

Latest Information Update: 18 Jan 2016

Price : $50

At a glance

  • Originator Theravance Biopharma
  • Class Aza compounds; Benzamides; Cyclohexanes; Heterocyclic bicyclo compounds; Laxatives; Morphine derivatives; Opioid analgesics; Small molecules; Tropanes
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Constipation; Pain

Most Recent Events

  • 10 Sep 2015 Pharmacokinetics data from a phase I trial in healthy volunteers released by Theravance Biopharma
  • 31 Dec 2014 Theravance Biopharma completes a phase I trial in Pain and opioid induced Constipation (In volunteers) in Australia (PO) (ACTRN12614001152617)
  • 16 Oct 2014 Phase-I clinical trials in Pain in Australia (PO) (ACTRN12614001152617)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top